Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Early diagnosis and targeted anti-inflammatory treatments can improve outcomes in androgenetic alopecia with perifollicular inflammation and fibrosis.

Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.

Baricitinib works better in adolescents than adults for treating severe alopecia areata.

Low-Level Laser Therapy (LLLT) is a safe and effective treatment for common hair loss, but more research is needed to find the best power and wavelength for treatment.

Low-level red light therapy can shorten eye length in some myopic children.

Early recognition and a team approach are crucial for managing diffuse alveolar hemorrhage in antiphospholipid syndrome.

Androgenetic alopecia is a condition causing noticeable hair loss, especially in middle age, which is more severe than normal balding.

The Sinclair Shedding Scale is effective for diagnosing Alopecia Areata Incognita and monitoring treatment success.

Recognizing LET and AITD can help diagnose SLE early for better treatment.

Intramuscular triamcinolone acetonide is an effective treatment for severe alopecia areata, especially in males.

Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.

The LTF gene may help predict and manage nonspecific orbital inflammation.

Some people with primary cicatricial alopecia also have inflammatory bowel disease, suggesting a possible connection.

Researchers found a new genetic mutation linked to a hair condition in a Japanese boy.

Intestinal intraepithelial lymphocytes are crucial for gut immunity and maintaining the mucosal barrier.

JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.

Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.

The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.

A rare case showed alopecia areata and lichen planus occurring together in one person.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Diagonal earlobe and preauricular creases may indicate higher coronary artery disease risk in men.

Long-lived proteins may predict age-related diseases.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Upadacitinib may cause hair loss.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

Ritlecitinib improves emotional well-being and activity levels in alopecia areata patients.

Low-dose oral minoxidil often improves hair loss, and early treatment of traction alopecia is effective but harder if delayed.

CS12192 effectively treats alopecia areata with better safety than current options.